Correlation of MMP-3 and MMP-9 with crohn's disease activity in children

Digestive Diseases and Sciences

Volumn 57, Issue 3, 2012, Pages 706-712

  Kofla Dlubacz, Anna ^a   Matusiewicz, Malgorzata ^a   Krzystek Korpacka, Malgorzata ^a   Iwanczak, Barbara ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Children; Crohn's disease; Inflammatory bowel disease; Metalloproteinases; PCDAI

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; STROMELYSIN; BIOLOGICAL MARKER; MMP3 PROTEIN, HUMAN;

ACCURACY; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; YOUDEN INDEX; BLOOD; HOSPITALIZATION; INFLAMMATION; PREDICTIVE VALUE; PROSPECTIVE STUDY;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84859505767     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1936-z     Document Type: Article

References (40)

1. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-839. (Pubitemid 36542523)
2. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther. 2006;318: 933-938. (Pubitemid 44268297)
3. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior? Annu Rev Cell Dev Biol. 2001;17:464-516.
4. Dollery CM, McEwan JR, Hanney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
5. Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis. 2003;62:1094-1099. (Pubitemid 37323575)
6. Freije JM, Díez-Itza I, Balbín M, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem. 1994;269: 16766-16773. (Pubitemid 24200439)
7. Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer. 2009;16:188.
8. Davies B, Miles DW, Happerfield LC, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer. 1993;67:1126-1131. (Pubitemid 23147516)
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-174. (Pubitemid 37328786)
10. Stearns ME, Stearns M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res. 1996;8:63-67.
11. Wood M, Fudge K, Mohler JL, et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and -2 expression in human prostate cancer. Clin Exp Metastasis. 1997;15:246-258. (Pubitemid 27240355)
12. Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol. 2000;120:241-246. (Pubitemid 30304217)
13. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis. 2007;39:733-739. (Pubitemid 47053808)
14. von Lampe B, Barthel B, Coupland SE, Riecken E-O, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63-73. (Pubitemid 30430413)
15. Santana A, Medina C, Paz-Cabrera MC, et al. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol. 2006;12: 6464-6472. (Pubitemid 44742583)
16. Sykes AP, Bhogal R, Brampton C, et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzensulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther. 1999;13:1535-1542. (Pubitemid 29516269)
17. Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol. 1997;158:1582-1590. (Pubitemid 127469511)
18. Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor immunoadhesin prevents T-cell mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol. 1998;160:4098-4103. (Pubitemid 28176121)
19. Medina C, Santana A, Paz MC, et al. Matrix metalloproteinases-9 modulates intestinal injury in rats with transmural colitis. J Leukoc Biol. 2006;79:954-962. (Pubitemid 44835582)
20. Gan X, Wong B, Wright SD, Cai T-Q. Production of matrix metalloproteinase -9 in CaCO-2 cells in response to inflammatory stimuli. J Interf Cytokine Res. 2001;21:93-98. (Pubitemid 32182245)
21. Iwańczak F, Krzesiek E, Iwańczak B. Epidemiologia wrzodzieja ?cego zapalenia jelita grubego i choroby Leśniowskiego-Crohna u dzieci z województwa dolnoślǎskiego i opolskiego. Pediatr Prakt. 2002;10:198-200.
22. Bentsen BS, Moum B, Ekbom A. Incidence of inflammatory bowel disease in children in southeastern Norway: a prospective population-based study 1990-1994. Scand J Gastroenterol. 2002;37: 540-545. (Pubitemid 34522919)
23. Kugathasan S, Judd RH, Hoffmann RG, et al. Wisconsin pediatric inflammatory bowel disease alliance. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003;143:525-531. (Pubitemid 37352514)
24. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology. 2004;126:1550-1560. (Pubitemid 38649872)
25. Medina C, Videla S, Radomski A, et al. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol. 2003;284:G116-G122. (Pubitemid 36076256)
26. Kobayashi K, Arimura Y, Goto A, et al. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium. J Pathol. 2006;209:376-383. (Pubitemid 43997747)
27. Gao Q, Meijer MJW, Schluter UG, et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis. 2007; 13:693-702. (Pubitemid 46909983)
28. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the porto criteria. J Pediatr Gastroenterol Nutr. 2005;41: 1-7.
29. Steinhart H, Gasche C, Arnott I, et al. Crohn's disease clinical classification, in working party of the 2005 Montreal world congress of gastroenterology. Toward an integrated clinical, molecular and serological classification of Crohn's disease. Can J Gastroenterol. 2005;19:5-36.
30. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. Pediatr Gastroenterol Nutr. 1991;12:439-447.
31. Hyams JS, Mandel F, Ferry GD, et al. Relationship of common laboratory parameters to the activity of Crohn's disease in children. J Pediatr Gastroenterol Nutr. 1992;14:216-222.
32. Pedersen G, Saermark T, Kirkegaard T, Brynskov J. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol. 2008;155:257-265.
33. Pender SL, Lionetti P, Murch SH, Wathan N, MacDonald TT. Proteolytic degradation of intestinal mucosal extracellular matrix after lamina propria T cell activation. Gut. 1996;39:284-290. (Pubitemid 26276008)
34. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester angiogenesis regulators. Blood. 2009;113:2835-2842.
35. Minderhoud IM, Samsom M, Oldenburg B. What predicts mucosal inflammation in Crohn's disease patients? Inflamm Bowel Dis. 2007;13:1567-1572.
36. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
37. Manfredi MA, Zurakowski D, Rufo PA, Walker TS, Fox VL, Moses MA. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008;14: 1091-1096.
38. Mroczko B, Groblewska M, Okulczyk B, Kědra B, Szmitowski M. The diagnostic value of matrix metalloproteinases 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Color Dis. 2010;25:1177-1184.
39. Yeh Y-Ch, Sheu B-S, Cheng H-Ch, Wang Y-L, Yang H-B, Wu J-J. Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancers can be biomarkers correlating with a poor survival. Dig Dis Sci. 2010;55:1649-1657.
40. Kirkegaard T, Hansen A, Bruun E, Brynskov J. Expression and localization of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004;53:701-709. (Pubitemid 38561449)